OXACILLIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oxacillin Sodium, and when can generic versions of Oxacillin Sodium launch?
Oxacillin Sodium is a drug marketed by Ani Pharms, Apothecon, Teva, Elkins Sinn, Eugia Pharma Speclts, Fresenius Kabi Usa, Hospira, Istituto Bio Ita Spa, Piramal Critical, Sagent Pharms, Sandoz, Steriscience, Watson Labs Inc, and Wockhardt Bio Ag. and is included in twenty-three NDAs.
The generic ingredient in OXACILLIN SODIUM is oxacillin sodium. There are thirty-eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the oxacillin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Oxacillin Sodium
A generic version of OXACILLIN SODIUM was approved as oxacillin sodium by SAGENT PHARMS on March 30th, 2012.
Summary for OXACILLIN SODIUM
US Patents: | 0 |
Applicants: | 14 |
NDAs: | 23 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 126 |
Clinical Trials: | 2 |
Patent Applications: | 4,360 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OXACILLIN SODIUM at DailyMed |
Recent Clinical Trials for OXACILLIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Haining Health-Coming Biotech Co., Ltd. | Phase 2 |
Alphacait, LLC | Phase 2 |
Federal University of São Paulo | Phase 4 |
Pharmacology for OXACILLIN SODIUM
Drug Class | Penicillin-class Antibacterial |